Several factors influence survival after a myocardial infarction: the most important factor seems to be the severity of left ventricular dysfunction.' The importance of left ventricular volume is now established, with ventricular enlargement identified as a significant risk factor in the development of cardiac failure. 2 In the Framingham Heart Study the risk of symptomatic heart failure developing in patients with a myocardial infarction was 7 to 10 times that of the normal population.3 In view of the appalling prognosis of chronic heart failure, even in those treated with angiotensin converting enzyme (ACE) inhibitors,4 much research has been aimed at treatments that might help to prevent the onset of heart failure.
Four large multicentre studies5-8 have now
reported beneficial effects of ACE inhibitors after a myocardial infarct but their relevance to current clinical practice remains unclear, largely because the populations randomised in these trials were very different owing to variation in inclusion and exclusion criteria. In SAVE, asymptomatic patients were screened for evidence of left ventricular dysfunction'; in AIRE, patients with clinical evidence of heart failure were recruited without objective assessment of ventricular function6; and the GISSI-3 and ISIS-4 trials included patients with suspected myocardial infarct presenting within 24 hours of the onset of pain.78
We wanted to assess the impact for our hospitals, in terms of reduced mortality, of a policy of ACE inhibition as suggested by the major trials and to estimate the costs of such a policy. We applied selection criteria from the four major trials to data from the Nottingham Heart Attack Register,9 which has documented all patients brought to the Nottingham hospitals (alive or dead) with suspected myocardial infarction during selected periods since 1973, to determine how applicable these trials were to patients from the Nottingham Health district.
Patients and methods
The methods of data collection and storage for the Nottingham Heart Attack Register have been described elsewhere.9 All patients admitted to the Nottingham hospitals with symptoms suggestive of acute myocardial infarction were identified through the medical records departments, accidents and emergency departments, and the records of the Nottingham Ambulance service. Most patients (75%) were admitted to coronary care but data from all admissions were used for analysis. A suspected myocardial infarct was defined as the primary working diagnosis, based upon the presenting history and initial electrocardiogram, as recorded by the admitting physician. A myocardial infarct was confirmed according to the criteria defined in the major trials.5-8 Details of management including Killip scores on admission, drugs prescribed while an inpatient and on discharge, the final diagnosis, and the outcome of the admission were obtained from the case notes after discharge or death of the patient. For this study we present data from 1989 and 1990, before ACE inhibitors were recommended after myocardial infarction.
Patients admitted with suspected myocardial infarction to the Nottingham hospitals were identified from their entry on the Heart Attack Register so that they matched as closely as possible the characteristics of the patients recruited into the four postinfarction studies. To do this we applied the selection criteria used to derive the population for the AIRE study to the Nottingham patients. Those Nottingham patients who fulfilled all the inclusion and exclusion criteria (and so who would have satisfied the entry requirements for the AIRE study) were used for this analysis.
We then applied the SAVE, GISSI-3, and ISIS-4 selection criteria to identify Nottingham patients who would have met the specific entry requirements for the SAVE, GISSI-3 and ISIS-4 studies.
We used the mortality data from these studies to calculate the potential impact on survival after a myocardial infarct for the Nottingham patients. These saved if patients were treated as described in the major trials. Drug costs were obtained from the British National Formulary.
Results

COMPARISON OF NOTTINGHAM PATIENTS WITH THOSE RECRUITED IN AIRE
AIRE study Figure 1 shows the patients considered for entry to the AIRE Study and the reasons for excluding patients from the study. More than 52 000 were considered; 30 717 (59% of all patients) had a confirmed myocardial infarction and almost 17 000 (55% of those with infarcts) had no signs (even transiently) of heart failure; 11 722 (38% of those with infarcts) were specifically excluded because of unstable angina, severe heart failure, because of intolerance of (or because they were already taking) ACE inhibitors, or because of sustained hypotension. This figure also includes 3323 (11% of those with infarcts) patients in whom long-term assessment or consent were impracticable. Overall, 2006 (7% of all those with infarcts) were recruited for the AIRE Study.
Nottingham patients Figure 1 also shows that in Nottingham 5405 patients had a suspected myocardial infarction between 1989 and 1990; over 1700 (33% of all patients) had a confirmed myocardial infarction; of these 564 (32% of those with infarcts) had no signs, even transiently, of heart failure. 1204 (68% of those with infarcts) had overt heart failure but 510 (29%) of those with infarcts) would have been specifically excluded by the AIRE criteria. This figure does not include patients in whom consent or long-term assessment was impracticable. Overall, 694 (39% of all those with infarcts) would have met the entry requirements for the AIRE study.
COMPARISON OF NOTTINGHAM PATIENTS WITH THOSE RECRUITED IN SAVE
SA VE study population Figure 2 shows the patients considered for entry to the SAVE study and the reasons why patients were excluded. Nearly 96 000 patients were considered for recruitment: 36 630 (38% of all patients) had an infarct confirmed but 5620 (15% of infarcts) of these were excluded owing to death within 3 days or age ineligibility; of the 31 010 (81% of those with infarcts) remaining 18 935 (52% of those with infarcts) were excluded because they had an ejection fraction > 40% on a radionuclide scan. A further 9844 (27% of infarcts) were excluded because of preexisting congestive cardiac failure, development of severe heart failure, unstable angina, sustained hypotension, and intolerance of 0 ACE inhibitors. Overall 2321 (6% of all those with infarcts) patients were randomised into the study.
Nottingham patients Figure 2 also All four recent trials confirm that there is benefit from treatment with an ACE inhibitor after acute myocardial infarction, with reductions in deaths, myocardial infarction, and progression to symptomatic heart failure. [5] [6] [7] [8] Because each trial recruited a different population of patients, it is important to establish how closely the trial populations approximated to the patients who are admitted to our hospitals.
Which trial is most appropriate for the types of patients admitted to the Nottingham hospitals with acute myocardial infarction? Nearly 40% of our patients with confirmed infarcts fit the AIRE study criteria.6 This reflects the high numbers of patients in the Nottingham population with clinical evidence of heart failure after admission. The reason for this is not clear because the numbers of patients receiving thrombolysis or with anterior infarcts were similar to those in the AIRE study. Fewer patients (7% of those with infarcts) in the AIRE study were eventually randomised to treatment but this also includes those patients in whom consent or long-term assessment was not possible. If the 40% of patients eligible in Nottingham were to receive the ACE inhibitor ramipril from around the fifth day after myocardial infarction (approximately 347 patients each year), we might expect to prevent 20 deaths in the next 15 months. The cost per life saved would be £5520. The cost benefit of the AIRE study seems even more remarkable when assessed at 30 days. This early effect on mortality was not described in the SAVE study, perhaps reflecting the different patient groups. The AIRE trial has, however, been criticised for failing to consider those patients with asymptomatic left ventricular dysfunction, who also have a high mortality after infarction.011 The AIRE study would have excluded a significant proportion of Nottingham patients (32% of those with confirmed infarcts) with no signs of heart failure, of whom 36% had anterior infarcts and nearly 50% were not treated with thrombolytic agents. Both these latter groups are thought to represent subgroups at particular risk of ventricular dysfunction and dilatation and these too may therefore benefit from ACE inhibition. '2 Few of our patients matched the SAVE criteria,5 so few patients might expect to benefit from receiving an ACE inhibitor around 11 days after myocardial infarction. The number of lives saved is small and because treatment was continued for 42 months the drug cost of saving a life is high, over ten times higher than in the GISSI-3 population and over six times higher than in the AIRE study. Furthermore before administration of captopril, nearly 900 patients would require formal assessment of ejection fraction, which using echocardiography in Nottingham 
